Webpackaging logo

e-Novelia wins the ‘Excellence in Pharma: Drug Delivery Devices’ award at CPhI Worldwide 2018

  • Nemera
Europe, Health, Pharmaceuticals, Active, Smart Packaging, Shows, Associations, Media, Packaging Awards

A team of industry experts awarded Nemera’s electronic add-on for ophthalmic droppers with a prestigious CPhI Award for Best Drug Delivery Device in its category.

On October 9th, during the CPhI Pharma Awards Gala, e-Novelia®, Nemera’s electronic add-on for ophthalmic droppers, was celebrated as the best-in-class innovation displayed at the show for “Excellence in Pharma: Drug Delivery Devices”.

e-Novelia®, Nemera’s smart ophthalmic add-on, has been designed to make patients’ life easier by offering increased comfort and optimized adherence to their treatments.

It works in combination with Nemera’s preservative-free multidose eye dropper Novelia®.

e-Novelia® incorporates cutting-edge technology and unique features. Nemera have designed and developed the device to add new functions which couldn’t be provided by standard mechanical devices.

Patients will benefit from enhanced instructions for use, immediate usage feedback and compliance information.

e-Novelia® combines these electronic benefits with improved ergonomics using mechanical features to make the device easier to activate and electronic functions to assist the patient in delivering drops accurately to the eyes.

This new technology will also be useful for healthcare professionals to tailor treatments and for researchers to perform more efficient clinical studies for example.

e-Novelia® has been designed to improve patients’ interaction with their drug by assisting them with:

  • Digitalized and interactive Instructions For Use through mobile application and on-device screen
  • Reminders to take their dose
  • Reminders to reload the device with a new drug bottle
  • Information about their drug: expiry date, dosage, batch number
  • Feedback and guidance to use their device the right way: tilt and shaking indication, buzzer, detection of wrong usage
  • Improved ergonomy and user friendliness featuring an eye cup and a bottle squeezing aid

Nemera’s smart eyedropper showcases several electronic features, which could be transferred across multiple device platforms:

  • Compliance rate
  • Treatment history
  • Remaining volume indication
  • Optimal position for drop into eye (via traffic lights)
  • Actuation ease of use
  • User instructions
  • Smartphone application and notifications
  • Shaking formulation indication
  • RFID tag on eyedropper bottle to collect data

“We are absolutely thrilled to receive this prestigious award.” – said Denise Johnston, VP Global Sales – “The Novelia PFMD platform is already a huge success in the market, improving patients’ daily lives by giving them an option on Preservative-Free formulations in a multi-dose eye dropper bottle, reducing allergic reactions and itchiness due to preservatives. Our innovation teams are blazing a trail on developing electronic devices to further enhance the patient experience with Novelia and these features can even be used universally for many of our other devices. It is wonderful to see this work recognized as being cutting-edge and hugely motivating for our teams. Like our motto says ‘We put patients first’”

Established in 2004, the CPhI Pharma Awards are among the most prestigious recognitions within the Pharmaceutical industry. The Awards celebrate thinkers and creators breaking new ground and strongly advocate companies committed to driving the industry forward.

See also

Nemera's RetroNose enhances therapeutic efficacy of nasal treatments

The number of applications through the nasal route is expanding, either for local treatments (e.g. chronic rhinosinusitis) or for systemic treatments (e.g. migraine, etc.). The clinical efficacy of a nasal treatment depends on how it is deposited in the nose, because the pharmaceutical target (local, systemic, brain) is directly related to a specific nasal anatomical site. That’s why Nemera has collaborated with CEPR to develop a different and portable delivery technology called RetroNose for a better drug deposition in the distal region of the nose, without lung deposition.

Safelia 1ml and 2.25ml autoinjectors designed to be patient and syringe friendly

Nemera’s new generation 2-step autoinjector platforms are suitable for fluid to highly viscous injections. Safelia® has been designed to ease patient self-injection experience and to deliver even the most challenging drugs (viscous formulations up to several Centipoise, sustain released, concentrated, fragile and shear sensitive formulations, either in subcutaneous or intramuscular layers, on two platforms: up to 1ml or up to 2.25ml delivery).

  • Company News
  • English
  • Modified 09 Jan 2019
  • Hits 977